KA
BBIO icon

Kovack Advisors’s BridgeBio Pharma BBIO Stock Holding History

Kovack Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$274K Buy
3,675
+850
+30% +$59.5K 0.01% 843
2026
Q1 		$210K Sell
2,825
-7,475
-73% -$542K 0.01% 910
2025
Q4 		$788K Buy
+10,300
New +$676K 0.04% 447

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Kovack Advisors's BBIO Position: Q2 2026 in Review

Kovack Advisors increased its BridgeBio Pharma (BBIO) stake by 30% in Q2 2026, buying an estimated $59.5K and bringing the position to 3,675 shares worth $274K. The position accounts for 0.01% of the portfolio, ranked #843.

Kovack Advisors first reported a position in BBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $788K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Kovack Advisors held 3,675 shares of BridgeBio Pharma worth $274K as of Q2 2026.
  • Kovack Advisors bought 850 BridgeBio Pharma shares in Q2 2026, an estimated $59.5K.
  • BridgeBio Pharma made up 0.01% of Kovack Advisors's portfolio in Q2 2026, its #843 holding.
  • Kovack Advisors first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 3 quarters since.
  • Kovack Advisors's BridgeBio Pharma position peaked at $788K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.